Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Lodewijk A.A. Brosens

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1341-8994; OpenAlex author ID A5037416658. Sources: ClinicalTrials.gov.

Their work

Papers
49 (first author 4, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
162
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 1 trial · 2018: none · 2019: 3 papers · 2020: 2 papers · 2021: 7 papers · 2022: 9 papers · 2023: 3 papers · 2024: 11 papers · 2025: 6 papers · 2026: 4 papers

Papers 49

  1. Pancreatic cancer risk and survival in patients with Lynch syndrome: a nationwide Dutch cohort study. Co-author DOI 10.1016/j.eclinm.2026.103755↗
  2. WNT7B drives a program for pancreatic cancer subtype switching and progression. Co-author DOI 10.1016/j.isci.2026.115050↗
  3. Gastrointestinal symptoms and health-related quality of life before and after pancreatectomy for pancreatic cancer (GO-PANC): longitudinal nationwide study. Co-author DOI 10.1093/bjs/znag122↗
  4. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  5. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  6. Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis. Co-author DOI 10.1007/s10689-025-00512-5↗
  7. Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study. Co-author DOI 10.1016/j.ejca.2025.116065↗
  8. Germline Pathogenic Variants in Patients with Pancreatic Ductal Adenocarcinoma and Extra-Pancreatic Malignancies: A Nationwide Database Analysis. Last author DOI 10.1016/j.modpat.2025.100709↗
  9. Tumor gene expression is associated with venous thromboembolism in patients with ductal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.thromres.2024.109240↗
  10. Perineural Invasion is an Important Prognostic Factor in Patients With Radically Resected (R0) and Node-negative (pN0) Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006320↗
  11. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  12. Precursor lesions in familial and hereditary pancreatic cancer. First author DOI 10.1007/s10689-024-00359-2↗
  13. Radiation response assessment of organoids derived from patients with pancreatic cancer. Co-author DOI 10.1016/j.ctro.2024.100829↗
  14. Qualitative flow metabolic phenotype of pancreatic cancer. A new prognostic biomarker? Co-author DOI 10.1016/j.hpb.2023.11.010↗
  15. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study. Co-author DOI 10.1097/sla.0000000000006004↗
  16. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗
  17. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… Co-author DOI 10.1186/s13063-024-08295-3↗
  18. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis. Co-author DOI 10.1245/s10434-024-15070-w↗
  19. Automatic quantification of tumor-stroma ratio as a prognostic marker for pancreatic cancer. Co-author DOI 10.1371/journal.pone.0301969↗
  20. Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer. Co-author DOI 10.2967/jnumed.123.266262↗
  21. Limited Role of the Apparent Diffusion Coefficient (ADC) for Tumor Grade and Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diagnostics14060573↗
  22. Impact of network treatment in patients with resected pancreatic cancer on use and timing of chemotherapy and survival. Co-author DOI 10.1093/bjsopen/zrad006↗
  23. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. Co-author DOI 10.1186/s12885-023-11141-5↗
  24. Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival… Co-author DOI 10.1245/s10434-023-13465-9↗
  25. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metas… Co-author DOI 10.1007/s00428-021-03205-3↗
  26. Impact of multicentre diagnostic workup in patients with pancreatic cancer on repeated diagnostic investigations, time-to-diagnosis and time-to-treatment: A na… Co-author DOI 10.1016/j.ejso.2022.05.031↗
  27. Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. Co-author DOI 10.1080/14728222.2022.2021397↗
  28. Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study. Co-author DOI 10.1093/bjs/znac272↗
  29. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  30. Detecting Lynch syndrome in pancreatic ductal adenocarcinoma FNA cytology based on cancer history and immunocytochemistry. Last author DOI 10.1136/gutjnl-2021-326033↗
  31. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11664-4↗
  32. Correction to: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic C… Co-author DOI 10.1245/s10434-022-12182-z↗
  33. Comparing Survival after Resection of Pancreatic Cancer with and without Pancreatic Cysts: Nationwide Registry-Based Study. Co-author DOI 10.3390/cancers14174228↗
  34. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis. Co-author DOI 10.1016/j.ejso.2020.11.145↗
  35. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  36. Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review. Co-author DOI 10.1093/bjs/znaa031↗
  37. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. First author DOI 10.1136/gutjnl-2020-320726↗
  38. Neoantigen Quantity and Quality in Relation to Pancreatic Cancer Survival. First author DOI 10.3389/fmed.2021.751110↗
  39. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Co-author DOI 10.3390/cancers13133119↗
  40. Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/thno.60350↗
  41. Diagnostic accuracy of contrast-enhanced diffusion-weighted MRI for liver metastases of pancreatic cancer: towards adequate staging and follow-up of pancreatic… Co-author DOI 10.1186/s12885-020-07226-0↗
  42. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled t… Co-author DOI 10.1186/s13063-020-4180-z↗
  43. Why is pancreatic cancer so deadly? The pathologist's view. Co-author DOI 10.1002/path.5260↗
  44. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Co-author DOI 10.1073/pnas.1911273116↗
  45. Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. Co-author DOI 10.3390/cancers11081152↗
  46. Pathology of Pancreatic Cancer Precursor Lesions. First author DOI 10.1016/j.path.2016.05.004↗
  47. Diagnostic value of a pancreatic mass on computed tomography in patients undergoing pancreatoduodenectomy for presumed pancreatic cancer. Co-author DOI 10.1016/j.surg.2015.03.008↗
  48. Pancreatic adenocarcinoma pathology: changing "landscape". Co-author DOI 10.3978/j.issn.2078-6891.2015.032↗
  49. Preoperative characteristics of patients with presumed pancreatic cancer but ultimately benign disease: a multicenter series of 344 pancreatoduodenectomies. Co-author DOI 10.1245/s10434-014-3810-7↗

Trials 1

  1. Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics Principal investigator NCT05669287↗

Closest collaborators

The 25 strongest of 162 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 22 shared papers, 2014–2026 · strength 2.90
  2. Hjalmar C. van Santvoort · 17 shared papers, 2014–2026 · strength 2.29
  3. Martijn W.J. Stommel · 14 shared papers, 2021–2026 · strength 2.22
  4. Ignace H. J. T. de Hingh · 16 shared papers, 2014–2026 · strength 2.11
  5. Izaak Quintus Molenaar · 15 shared papers, 2014–2026 · strength 1.93
  6. Bas Groot Koerkamp · 12 shared papers, 2021–2026 · strength 1.66
  7. Lois A. Daamen · 11 shared papers, 2021–2026 · strength 1.64
  8. Bert A. Bonsing · 12 shared papers, 2014–2025 · strength 1.43
  9. Vincent Erwin de Meijer · 9 shared papers, 2021–2026 · strength 1.27
  10. Claudio Luchini · 10 shared papers, 2019–2025 · strength 1.27
  11. Joanne Verheij · 10 shared papers, 2021–2025 · strength 1.24
  12. Valentyna Kryklyva · 6 shared papers, 2021–2025 · strength 1.07
  13. Lydia G. van der Geest · 6 shared papers, 2022–2026 · strength 1.05
  14. Geert Kazemier M · 7 shared papers, 2021–2026 · strength 0.95
  15. Casper H.J. van Eijck · 7 shared papers, 2014–2026 · strength 0.91
  16. Johanna W. Wilmink · 6 shared papers, 2021–2026 · strength 0.89
  17. Iris W.J.M. van Goor · 6 shared papers, 2021–2024 · strength 0.88
  18. Judith de Vos‐Geelen · 5 shared papers, 2022–2026 · strength 0.83
  19. Robert C. Verdonk · 6 shared papers, 2022–2024 · strength 0.81
  20. Hanneke W.M. van Laarhoven · 5 shared papers, 2022–2026 · strength 0.79
  21. Thijs J. Schouten · 6 shared papers, 2021–2025 · strength 0.77
  22. Sebastiaan Festen · 6 shared papers, 2021–2025 · strength 0.77
  23. Cees J. H. M. van Laarhoven · 4 shared papers, 2020–2024 · strength 0.77
  24. Hanneke W. Wilmink · 4 shared papers, 2025–2026 · strength 0.74
  25. Aldo Scarpa · 6 shared papers, 2019–2025 · strength 0.74

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.